Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Privia Health Group, Inc. (Nasdaq: PRVA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Privia Health is a Delaware-incorporated, technology-driven physician enablement company based in Arlington, Virginia, and its filings offer detailed information about its financial condition, operations, governance, and material events.
Among the most frequently referenced documents are current reports on Form 8-K, which Privia Health uses to announce quarterly financial results, guidance updates, and other significant developments. For example, the company has filed 8-Ks to furnish press releases covering its first, second, and third quarter results, including metrics such as total revenue, net income, Adjusted EBITDA, Implemented Providers, Value-Based Care Attributed Lives, Practice Collections, Care Margin, and Platform Contribution. It has also filed 8-Ks to describe material events like the definitive agreement to acquire an Accountable Care Organization business from Evolent Health, Inc., and changes in its Board of Directors.
Investors analyzing PRVA can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR) to review segment information, risk factors, non-GAAP reconciliations, and detailed discussions of the company’s value-based care model and physician enablement platform. These filings also elaborate on regulatory risks, relationships with medical groups and providers, and dependencies on key technology vendors.
On Stock Titan, Privia Health filings are complemented by AI-powered summaries that explain the key points of lengthy documents such as 10-Ks and 10-Qs, and highlight notable items in 8-Ks. Users can quickly see what changed from prior periods, how management describes performance in value-based care programs like the Medicare Shared Savings Program, and where guidance or risk disclosures have been updated. The platform also surfaces relevant insider and governance-related filings, helping readers track board appointments, compensation plans, and other corporate actions disclosed to the SEC.
Privia Health Group EVP & General Counsel Edward C. Fargis reported two stock sales that were required to cover taxes on vested restricted stock units. On March 6, 2026, he sold 4,394 shares at $23.15 per share, followed by 4,949 shares at $22.84 per share on March 9, 2026. The footnote explains these were nondiscretionary “sell to cover” transactions to satisfy tax withholding obligations, rather than elective open-market sales. After the transactions, he directly owned 83,711 shares of Privia Health Group common stock.
Privia Health Group, Inc. Executive Vice President and Chief Financial Officer David Mountcastle reported open-market sales totaling 11,006 shares of common stock on March 6 and March 9, at prices of $23.15 and $22.84 per share.
According to the filing, these were nondiscretionary sell-to-cover transactions required to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units. After the transactions, he directly holds 161,903 shares and indirectly holds 8,695 shares through his spouse.
Parth Mehrotra reported a sale of common stock. The filing shows a sale of 21,440 common shares on 03/06/2026 for $496,357.44 under Form 144. The filing also records the vesting of 23,134 restricted shares on 03/05/2026 as compensation.
PRVA filed a Form 144 disclosing that 18,865 shares of common stock are covered by a sale notice related to restricted stock vesting on 03/06/2026.
The filing also lists a prior transaction of 21,440 common shares by Parth Mehrotra on 03/06/2026.
PRVA reported a Form 144 notice to sell 4,949 shares of common stock associated with restricted stock vesting (listed as "Issuer" and "Compensation") dated 03/06/2026.
The filing also records securities sold during the past three months: 4,394 shares on 03/06/2026 by Edward C. Fargis.
PRVA filing notifies proposed dispositions of common stock under Rule 144 and lists recent completed sales by a reporting person. The excerpt shows four reported sales by David Mountcastle: 23,887 shares on 12/12/2025, 5,361 on 02/26/2026, 7,697 on 02/27/2026, and 5,177 on 03/06/2026. It also lists 5,829 common shares tied to restricted stock vesting on 03/06/2026.
David Mountcastle reports proposed sale of 5,177 shares of common stock issued upon restricted stock vesting on 03/05/2026. The filing also lists recent open-market dispositions by Mr. Mountcastle in the past three months, including 23,887 shares on 12/12/2025, 5,361 shares on 02/26/2026, and 7,697 shares on 02/27/2026.
Privia Health Group, Inc. director Matthew Shawn Morris reported option exercises and related share sales. On February 26 and 27, 2026, he exercised stock options covering 24,338 shares of common stock at an exercise price of $2.00 per share.
He then sold 24,338 shares of common stock in open-market transactions at weighted average prices around $25.00 per share, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 68,188 shares of common stock and held additional shares indirectly through a trust and Emerald Family, LLC.